#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Metastases to central nervous system Pulmonary arterial hypertension Oesophageal carcinoma Cerebellar ataxia Marginal zone lymphoma refractory Burkitt's lymphoma Congenital disorder of glycosylation Osteosarcoma recurrent Metachromatic leukodystrophy Acquired haemophilia Shprintzen-Goldberg syndrome Synovial sarcoma metastatic Frontotemporal dementia Bone marrow disorder Adenoid cystic carcinoma More trials…

    Learn about Rare Diseases

    Crigler-Najjar syndrome – Life with Disease Malignant fibrous histiocytoma Synovial sarcoma metastatic Epidermolysis bullosa – Treatment SAPHO syndrome – Treatment Toxic epidermal necrolysis – Diagnostics Ornithine transcarbamoylase deficiency – Diagnostics Hepatoblastoma – Diagnostics IgA nephropathy – Trials in Disease Hereditary neuropathic amyloidosis – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Keto-Leucine Calcium Rosuvastatin Calcium Canagliflozin Abemaciclib (-)-PHENSERINE TARTRATE Gremubamab Camphor Atomoxetine Fianlimab Levomethadone Hydrochloride Aminocaproic Acid Bi 764532 VERT-002 Gad20-209-Fsp-A3 Rivaroxaban LYSERGIDE MB-001 Lt3001 Tx200-Tr101 Spartalizumab More therapies…

    Learn about Your Condition

    Anxiety Hypertrophic scar Asplenia Fallopian tube cancer stage IV Renal cell carcinoma stage IV B-cell lymphoma refractory Erectile dysfunction Angina pectoris Mesothelioma malignant Mantle cell lymphoma stage III Peritoneal abscess Vulvar dysplasia Optic glioma Endotracheal intubation Anal fissure More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Cliniques Universitaires Saint-Luc

Cliniques Universitaires Saint-Luc

Hippokrateslaan 10, Batiment 54, Woluwe-Saint-Lambert, 1200, Belgium

Want to learn more about this study or check if you can participate? Contact us.

  • Study Comparing Relatlimab-Nivolumab Combination with Regorafenib or Trifluridine-Tipiracil for Patients with Advanced Metastatic Colorectal Cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Tipiracil Hydrochloride
    • Trifluridine
    • Regorafenib
    Austria Belgium Czechia France Germany Italy +4

  • Study on the Effectiveness and Safety of CAM2029 Compared to Octreotide and Lanreotide in Patients with Gastroenteropancreatic Neuroendocrine Tumors

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Lanreotide
    • Octreotide
    Belgium France Germany Hungary Italy The Netherlands +2

  • Study on Lenalidomide, Tafasitamab, and Rituximab for Treating Diffuse Large B-Cell Lymphoma in Patients Aged 80 and Older

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Vincristine
    • Cyclophosphamide
    • Doxorubicin
    Belgium France

  • Study of Tafasitamab, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Lenalidomide
    • Rituximab
    • Tafasitamab
    Austria Belgium Czechia Denmark Finland France +10

  • Study on Giredestrant and Fulvestrant with CDK4/6 Inhibitor for Patients with ER+ HER2-Negative Advanced Breast Cancer Resistant to Endocrine Therapy

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Giredestrant
    • Leuprorelin
    • Abemaciclib
    Austria Belgium Finland France Germany Greece +7

  • Study on Guselkumab and Etanercept for Treating Chronic Plaque Psoriasis in Children Aged 6 to 17 Years

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Etanercept
    • Guselkumab
    Belgium Germany Hungary Italy Poland

  • Study of BMS-986466 with Adagrasib and Cetuximab for Patients with KRAS G12C-mutant Advanced Solid Tumors

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    • Bbp-398
    • Adagrasib
    • Cetuximab
    Belgium Finland France Italy Spain

  • Study on Baricitinib for Hospitalized Patients with Severe or Critical COVID-19

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Lung disorder
    Investigated Drugs:
    • Baricitinib
    Austria Belgium Czechia France Germany Greece +8

  • Study of Giredestrant Combined with Pertuzumab-Trastuzumab (Phesgo) for Patients with Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally Advanced or Metastatic Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Anhydrous Docetaxel
    • Giredestrant
    • Anastrozole
    Belgium France Germany Hungary Italy Poland +2

  • Study on the Effectiveness and Safety of Bemcentinib for Hospitalized Patients with Moderate COVID-19

    Not recruiting

    2 1
    Investigated Diseases:
    • Lung disorder
    Investigated Drugs:
    • Bemcentinib
    Belgium Czechia France Greece Ireland Italy +4
Previous Page
1 … 58 59 60 61 62 … 67
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!